Skip to Main Content

Paper Details

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.
Nat Commun
176
2021
Author NameAffiliation
Malina A Bakowskia division of The Scripps Research Institute
Holly HammondDepartment of Microbiology and Immunology University of Maryland School of Medicine
James LogueDepartment of Microbiology and Immunology University of Maryland School of Medicine
Romel RosalesIcahn School of Medicine at Mount Sinai
Romel RosalesGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Stuart WestonDepartment of Microbiology and Immunology University of Maryland School of Medicine
Kris M WhiteIcahn School of Medicine at Mount Sinai
Kris M WhiteGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreIcahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Matthew B FriemanDepartment of Microbiology and Immunology University of Maryland School of Medicine
Matthew B FriemanDepartment of Microbiology and Immunology University of Maryland School of Medicine
  • 1 - 12

Datasets